|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. First International Latex ConferenceCDC and the Food and Drug Administration (FDA) will cosponsor the first International Latex Conference November 5-7, 1992, in Baltimore. The conference will provide an opportunity for health-care professionals, scientists, industry, and regulatory agencies to present data and exchange information about the issues of hypersensitivity reaction to latex medical devices. The program will include speakers, oral and poster presentations, and a panel discussion. Topics will include latex chemistry, clinical studies, protein quantification and identification, epidemiology of latex hypersensitivity, diagnostic testing methods, prevention strategies, and approaches of manufacturers and producers. Additional information is available from the FDA International Latex Conference, in care of Crosspaths Management Systems, Inc., Two Wisconsin Circle, Suite 660, Chevy Chase, MD 20815; telephone (800) 5CPATHS ((800) 527-2847). Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 08/05/98 |
|||||||||
This page last reviewed 5/2/01
|